BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 4346603)

  • 1. Cushing's disease with periodic hormonogenesis: one explanation for paradoxical response to dexamethasone.
    Brown RD; Van Loon GR; Orth DN; Liddle GW
    J Clin Endocrinol Metab; 1973 Mar; 36(3):445-51. PubMed ID: 4346603
    [No Abstract]   [Full Text] [Related]  

  • 2. Periodic remission in Cushing's disease with paradoxical dexamethasone response: an expression of periodic hormonogenesis.
    Liberman B; Wajchenberg BL; Tambascia MA; Mesquita CH
    J Clin Endocrinol Metab; 1976 Oct; 43(4):913-8. PubMed ID: 185234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Behavior of adrenocorticotropic internal secretions in Cushing's syndrome].
    Silvestrini F; D'Alonzo R
    Schweiz Med Wochenschr; 1970 Oct; 100(40):1680-4. PubMed ID: 4335210
    [No Abstract]   [Full Text] [Related]  

  • 4. Diagnosis of Cushing's syndrome. The differentiation between adrenocortical hyperplasia and adrenocrotical adenoma by means of lysine-vasopressin.
    Bethge H; Bayer JM; Winkelmann W
    Acta Endocrinol (Copenh); 1969 Jan; 60(1):47-59. PubMed ID: 4308289
    [No Abstract]   [Full Text] [Related]  

  • 5. Suppression of ACTH by cortisol in dexamethasone-nonsuppressible Cushing's disease.
    Carey RM
    N Engl J Med; 1980 Jan; 302(5):275-9. PubMed ID: 6243171
    [No Abstract]   [Full Text] [Related]  

  • 6. Cushing's syndrome caused by a metyrapone responsive adrenocortical adenoma.
    Crystal RG; Rose LI; Jagger PI; Lauler DP
    J Clin Endocrinol Metab; 1970 Aug; 31(2):199-203. PubMed ID: 4317343
    [No Abstract]   [Full Text] [Related]  

  • 7. Anomalous response to metyrapone in Cushing's syndrome due to adrenocortical adenoma.
    Pennington LF; Kreisberg RA; Hershman JM
    J Clin Endocrinol Metab; 1970 Jan; 30(1):125-7. PubMed ID: 4311614
    [No Abstract]   [Full Text] [Related]  

  • 8. [A case of Cushing's disease with paradoxical response to dexamethasone].
    Kubo M; Nakagawa K; Akikawa K; Matsubara M; Ishizuka T; Nakagawa S
    Nihon Naika Gakkai Zasshi; 1986 Jan; 75(1):75-82. PubMed ID: 3009668
    [No Abstract]   [Full Text] [Related]  

  • 9. Lack of responsiveness to L-dopa in Cushing's disease.
    Krieger DT
    J Clin Endocrinol Metab; 1973 Feb; 36(2):277-84. PubMed ID: 4345691
    [No Abstract]   [Full Text] [Related]  

  • 10. Radioimmunoassayable ACTH in dexamethasone nonsuppressible Cushing's syndrome.
    Rayyis SS; Bethune JE
    J Clin Endocrinol Metab; 1969 Sep; 29(9):1231-7. PubMed ID: 4309156
    [No Abstract]   [Full Text] [Related]  

  • 11. [Investigation of Cushing's syndrome. The diagnostic value of the dexamethasone suppression test, the metopirone test and the CRF test].
    Johannesen O; Jørgensen H; Frey H; Norman N
    Tidsskr Nor Laegeforen; 1989 Sep; 109(26):2678-82. PubMed ID: 2554527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal rhythm in the response of urinary 17-OHCS to metopirone in Cushing's syndrome due to bilateral adrenal hyperplasia.
    Takebe K
    J Clin Endocrinol Metab; 1973 Mar; 36(3):433-8. PubMed ID: 4685385
    [No Abstract]   [Full Text] [Related]  

  • 13. Transition from pituitary-dependent to adrenal-dependent Cushing's syndrome.
    Hermus AR; Pieters GF; Smals AG; Pesman GJ; Lamberts SW; Benraad TJ; van Haelst UJ; Kloppenborg PW
    N Engl J Med; 1988 Apr; 318(15):966-70. PubMed ID: 2832758
    [No Abstract]   [Full Text] [Related]  

  • 14. "Normal suppression" to dexamethasone in Cushing's disease: an expression of decreased metabolic clearance for dexamethasone.
    Caro JF; Meikle AW; Check JH; Cohen SN
    J Clin Endocrinol Metab; 1978 Sep; 47(3):667-70. PubMed ID: 233679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cushing's syndrome with dual pituitary-adrenal control.
    Choi Y; Werk EE; Sholiton LJ
    Arch Intern Med; 1970 Jun; 125(6):1045-9. PubMed ID: 4378134
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies of ACTH secretion control in 116 cases of Cushing's syndrome.
    Raux MC; Binoux M; Luton JP; Gourmelen M; Girard F
    J Clin Endocrinol Metab; 1975 Feb; 40(2):186-97. PubMed ID: 163970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reliability and significance of the dexamethasone suppression test in Cushing's disease.
    N Engl J Med; 1967 Aug; 277(8):431. PubMed ID: 4378315
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypercortisolism.
    Howanitz PJ; Howanitz JH
    Clin Lab Med; 1984 Dec; 4(4):683-702. PubMed ID: 6096077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of cyproheptadine on plasma ACTH and cortisol secretion in a patient with Cushing's disease].
    Esposito V; D'Alessandro B; Bellastella A; Iacono G; Bizzarro A; Officioso A; Piccolo C
    Boll Soc Ital Biol Sper; 1976 Nov; 52(22):1901-5. PubMed ID: 194608
    [No Abstract]   [Full Text] [Related]  

  • 20. Observations and comments on failure of dexamethasone suppression.
    Linn JE; Bowdoin B; Farmer TA; Meador CK
    N Engl J Med; 1967 Aug; 277(8):403-5. PubMed ID: 4378314
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.